You are here

Generic Version of Zithromax Gains FDA Approval

SCHAUMBURG, Ill., Dec. 14 /PRNewswire-FirstCall/ -- American Pharmaceutical Partners, Inc. (NASDAQ:APPX) , today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Azithromycin for Injection, the generic equivalent of Pfizer Inc.'s Zithromax(R). Sales of this product exceeded $69 million in 2004 and were more than $74 million through the first nine months of 2005, according to IMS. APP expects to commence marketing Azithromycin in the 2006 first quarter, with GPO contracts in place.

"The addition of Azithromycin expands our anti-infective portfolio to 18 products and extends to 11 the number of different classes of anti-infectives APP offers," said Patrick Soon-Shiong, M.D., chairman and chief executive officer. "Azithromycin is the sixth multi-source product approval APP has received this year."

Azithromycin will be available from APP in 500 mg vials. The product is preservative-free and AP rated and each vial will include a bar code and latex-free vial stopper.

Azithromycin for Injection is indicated for the treatment of community-acquired pneumonia and pelvic inflammatory disease, when caused by susceptible microorganisms.

Source: American Pharmaceutical Partners, Inc.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs